TITLE

Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells

AUTHOR(S)
Ma, Yongsheng; Carter, Eric; Wang, Xiaomei; Shu, Chang; McMahon, Gerald; Longley, B. Jack
PUB. DATE
February 2000
SOURCE
Journal of Investigative Dermatology;Feb2000, Vol. 114 Issue 2, p392
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Summary Mastocytosis is a neoplastic disease caused at least in part by somatic mutations of the c-KIT proto-oncogene resulting in constitutive activation of its protein product, KIT, the receptor tyrosine kinase for stem cell factor. KIT stimulates mast cell proliferation and prevents apoptosis of neoplastic mast cells. To develop potential therapies for mastocytosis we used indolinones, small molecules that inhibit tyrosine kinases. Four indolinone derivatives (SU4984, SU6663, SU6577, and SU5614) inhibited wild-type KIT, but variably inhibited constitutively activated KIT mutants. SU4984, SU6577, and SU5614 were effective against KIT with juxtamembrane activating mutations, whereas only SU6577 could suppress KIT containing either juxtamembrane or kinase domain activating mutations. Furthermore, SU4984, SU6577, and SU5614 killed neoplastic mast cells expressing a juxtamembrane-mutated KIT, whereas SU4984 and SU6577 killed neoplastic mast cells expressing KIT bearing a kinase domain mutation. These data show a direct correlation between inhibition of constitutively activated KIT and the death of neoplastic mast cells, and point to specific tyrosine kinase inhibitors as a potential therapy aimed directly at a cause of mastocytosis.
ACCESSION #
5518513

 

Related Articles

  • Key Decision Just After 3 Months Following TKI Initiation in CML: Better and not Difficult. HAZNEDAROGLU, Ibrahim C. // International Journal of Hematology & Oncology / UHOD: Uluslarar;2013 Supplement, Vol. 23 Issue 1, p1 

    A letter to the editor is presented regarding the use of tyrosine kinase inhibitor (TKI) in the management of chronic myeloid leukemia (CML) is presented.

  • Sorafenib.  // Reactions Weekly;10/13/2012, Issue 1423, p45 

    The article describes the case of a male patient who developed occlusive coronary artery disease while undergoing sorafenib therapy for metastatic renal cell carcinoma.

  • Sorafenib/sunitinib.  // Reactions Weekly;10/13/2012, Issue 1423, p45 

    The article describes the case of a 60-year-old man with clear cell renal cell carcinoma who experienced various toxicities while undergoing sorafenib/sunitinib therapy.

  • Sunitinib.  // Reactions Weekly;10/13/2012, Issue 1423, p45 

    The article describes the case of a 72-year-old man who developed acute adrenal insufficiency with thyrotoxicosis while undergoing sunitinib therapy for metastatic renal cell carcinoma.

  • Sunitinib.  // Reactions Weekly;10/13/2012, Issue 1423, p46 

    The article describes the case of a 27-year-old woman who experienced fatigue and heart failure while undergoing sunitinib therapy for gastrointestinal stromal tumour (GIST).

  • Sunitinib.  // Reactions Weekly;10/13/2012, Issue 1423, p46 

    The article describes the case of a 41-year-old woman who developed severe hypothyroidism while undergoing sunitinib therapy for progressive metastatic papillary renal cell cancer.

  • Erlotinib/warfarin interaction.  // Reactions Weekly;6/18/2011, Issue 1356, p16 

    The article describes the case of a 47-year-old man who developed an elevated international normalized ratio (INR) while receiving treatment with erlotinib for lung cancer and warfarin therapy for venous thromboembolism.

  • Nilotinib.  // Reactions Weekly;10/6/2012, Issue 1422, p36 

    The article describes the case of a 72-year-old who experienced elevated pulmonary artery pressure while undergoing nilotinib therapy for chronic phase chronic myeloid leukaemia (CML).

  • Sunitinib.  // Reactions Weekly;10/20/2012, Issue 1424, p46 

    The article describes the case of a 56-year-old man who developed hypertension while receiving the antiangiogenic agent sunitinib for the treatment of renal cell carcinoma.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics